Literature DB >> 23726764

IL-22 secreting CD4+ T cells in the patients with neuromyelitis optica and multiple sclerosis.

Wen Xu1, Rui Li, Yongqiang Dai, Aimin Wu, Honghao Wang, Chen Cheng, Wei Qiu, Zhengqi Lu, Xiaonan Zhong, Yaqing Shu, Allan G Kermode, Xueqiang Hu.   

Abstract

Interleukin (IL)-22 secreting CD4(+) T (Th22) cells and IL-22 are involved in the pathogenesis of autoimmune disease, but their role in neuromyelitis optica (NMO) and multiple sclerosis (MS) is unclear. We measured the proportion of Th22, Th17, CD4(+)IL-22(+)IL-17A(+) T cells and serum IL-22 in NMO and MS patients. The proportion of Th22 cells, Th17 cells and serum IL-22 were increased in patients with NMO and MS. Our findings suggest that increased Th22 cells may play an important role in the pathogenesis of NMO and MS.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  IL-22; IL-22 secreting CD4+ T cells; MS; NMO; Th22 cells

Mesh：

Substances：

Year:  2013        PMID： 23726764     DOI： 10.1016/j.jneuroim.2013.04.021

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  26 in total

1.  Th9 and Th22 immune response in young patients with type 1 diabetes.

Authors:  Monika Ryba-Stanisławowska; Paulina Werner; Agnieszka Brandt; Małgorzata Myśliwiec; Jolanta Myśliwska
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

Review 2.  T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.

Authors:  Itay Raphael; Saisha Nalawade; Todd N Eagar; Thomas G Forsthuber
Journal:  Cytokine       Date:  2014-10-30       Impact factor: 3.861

3.  Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase.

Authors:  P O Barros; T Cassano; J Hygino; T B Ferreira; N Centurião; T M Kasahara; R M Andrade; U C Linhares; A F B Andrade; C C F Vasconcelos; R Alvarenga; R Marignier; C A M Bento
Journal:  Clin Exp Immunol       Date:  2015-12-01       Impact factor: 4.330

4.  Interleukin-17- and interleukin-22-secreting myelin-specific CD4(+) T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients.

Authors:  Ana Cristina Wing; Joana Hygino; Thais B Ferreira; Taissa M Kasahara; Priscila O Barros; Priscila M Sacramento; Regis M Andrade; Solange Camargo; Fernanda Rueda; Soniza V Alves-Leon; Claudia Cristina Vasconcelos; Regina Alvarenga; Cleonice A M Bento
Journal:  Immunology       Date:  2015-12-02       Impact factor: 7.397

Review 5.  Effector T Cells in Multiple Sclerosis.

Authors:  Belinda J Kaskow; Clare Baecher-Allan
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

Review 6.  The Potential Role of T Helper Cell 22 and IL-22 in Immunopathogenesis of Multiple Sclerosis.

Authors:  Nazanin Arjomand Fard; Gholamreza Azizi; Abbas Mirshafiey
Journal:  Innov Clin Neurosci       Date:  2016-08-01

Review 7.  Aberrant Complement System Activation in Neurological Disorders.

Authors:  Karolina Ziabska; Malgorzata Ziemka-Nalecz; Paulina Pawelec; Joanna Sypecka; Teresa Zalewska
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

8.  IL-22-producing Th22 cells play a protective role in CVB3-induced chronic myocarditis and dilated cardiomyopathy by inhibiting myocardial fibrosis.

Authors:  Yujie Guo; Weifeng Wu; Zhihong Cen; Xiaomo Li; Qing Kong; Qiuxi Zhou
Journal:  Virol J       Date:  2014-12-30       Impact factor: 4.099

9.  Selective serotonin reuptake inhibitor attenuates the hyperresponsiveness of TLR2+ and TLR4+ Th17/Tc17-like cells in multiple sclerosis patients with major depression.

Authors:  Marisa C Sales; Taissa M Kasahara; Priscila M Sacramento; Átila D Rossi; Marcos Octávio S D Cafasso; Hugo A A Oyamada; Joana Hygino; Fabianna Alvim; Regis M Andrade; Cláudia Cristina Vasconcelos; Cleonice A M Bento
Journal:  Immunology       Date:  2020-11-23       Impact factor: 7.397

Review 10.  Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases.

Authors:  Qi Jiang; Guocan Yang; Fan Xiao; Jue Xie; Shengjun Wang; Liwei Lu; Dawei Cui
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.